Enanta Pharmaceuticals, Inc. (ENTA)
| Market Cap | 389.94M +202.0% |
| Revenue (ttm) | 69.21M +7.4% |
| Net Income | -61.98M |
| EPS | -2.47 |
| Shares Out | 29.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,933 |
| Open | 13.59 |
| Previous Close | 13.81 |
| Day's Range | 13.19 - 14.00 |
| 52-Week Range | 5.04 - 17.15 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 20.40 (+52.13%) |
| Earnings Date | May 11, 2026 |
About ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica... [Read more]
Financial Performance
In fiscal year 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ENTA stock is "Strong Buy." The 12-month stock price target is $20.4, which is an increase of 52.13% from the latest price.
News
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta announces first participant dosed in Phase 1 trial of EDP-978
Enanta (ENTA) Pharmaceuticals announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other…
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Seema Sheoran initiated coverage of Enanta (ENTA) with a Buy rating and $20 price target
Enanta Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
The company is advancing two RSV drug candidates, with zelicapavir showing strong Phase II efficacy and EDP-323 demonstrating rapid viral suppression. Three immunology programs are progressing, with KIT and STAT6 targeting major inflammatory diseases and all I&I efforts funded through early clinical stages.
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta files $150M mixed securities shelf
16:45 EST Enanta (ENTA) files $150M mixed securities shelf
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta reports Q1 EPS (42c), consensus (88c)
Reports Q1 revenue $18.6M, consensus $15.3M. Enanta’s (ENTA) cash, cash equivalents and short-term and long-term marketable securities totaled $241.9 million at December 31, 2025. Enanta expects that ...
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company presented robust RSV and immunology pipelines, highlighting phase II success for zelicapavir in high-risk adults and pediatrics, and strong preclinical data for EDP-323, KIT, STAT6, and X2 programs. Phase III RSV trials and multiple IND filings are planned for 2024.
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunol...
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for vir...
Enanta Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Recent advances include positive phase II-B RSV data in high-risk adults and expansion into immunology with new clinical candidates for KIT and STAT6 targets. IND filings for these programs are expected in 2026 and late next year, with a third immunology target to be announced soon.
Enanta Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
The company highlighted strong RSV data in high-risk adults, with reduced symptom duration and hospitalizations, and outlined progress in its immunology pipeline, including a best-in-class oral STAT6 inhibitor and a selective KIT inhibitor. Phase three RSV trials and new immunology programs are planned.
Enanta reports Q4 EPS (87c), consensus ($1.01)
Reports Q4 revenue $15.1M, consensus $15.97M. “This past quarter marked a pivotal period for Enanta (ENTA), with significant progress across our virology and immunology programs, highlighted by positi...
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Enanta (ENTA) with an Overweight rating and $17 price target The firm cites the recent Phase 2b data for zelicapavir in respiratory syncytial virus for the…
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunol...
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunol...
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunol...
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...